ANL: Adlai Nortye Ltd Company Total Debt

Brandmark of Adlai Nortye Limited (ANL)

Adlai Nortye Ltd. (ANL) is facing negative free cash flow due to R&D expenditures, as evidenced by current debt obligations on the GURU.Markets system chart, where 0.02 is the current value of the indicator. Risks are being mitigated through global clinical trials for advanced cancer drugs, while sales of the original drug in China support the company's liquidity.

ANL Adlai Nortye Ltd Company Debts (02/21/2024 - 10/31/2026)

Analytical breakdowns for Adlai Nortye Ltd. (ANL)

- stock price and consensus target price:
Share Price adlainortye.com|ANL - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Adlai Nortye Limited|ANL - Enterprise Value
- book value of equity indicators:
Net Asset Value per Share Adlai Nortye|ANL - Company Book Value|Market Value to Book Value adlainortye.com|ANL - Cumulative Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Adlai Nortye Ltd.|ANL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio adlainortye.com|ANL - Company Total Debt|Debts to Book Capitalization Adlai Nortye Limited|ANL - Company Long-Term Debt|Company Short-Term Loans and Borrowings Adlai Nortye|Immediate Liquidity adlainortye.com
- earnings and multiples data:
ANL - Net Profit
Summary company analytics:ANL Adlai Nortye Ltd
Finished products of Adlai Nortye

Assessing the operational resilience of Adlai Nortye Ltd. (ANL) requires an analysis of total borrowings, which, through financial debt metrics, reflect the overall debt load and the density of borrowed capital. For this developer of anti-tumor therapies, controlling this limit is critical, as stable demand for patented molecules must ensure the servicing of obligations without risking the loss of the business's financial stability.

Competitors of Adlai Nortye Ltd.

BeiGene Oncology - Company Aggregate Debt|Company Aggregate Debts HALO (Halozyme Therapeutics)|RVMD - Company Total Debt|Ascentage Pharma - Company Aggregate Debts|Company Cumulative Debt CG Oncology Inc|UroGen (URGN) - Company Debts|Bicara Corp - Aggregate Debt Obligations|Company Total Debt PSNL|ERAS: Aggregate Debt Obligations|Company Aggregate Debts DCTH|Company Total Debt Y-mAbs Therapeutics Inc YMAB|Aura Bio - Company Total Debt|Company Aggregate Debts Candel Therapeutics Inc. CADL|ARAY - Company Debts|Aggregate Debt Obligations SLS (SELLAS Life Sciences)|ACTU: Company Aggregate Debts|Company Cumulative Debt Citius Oncology Inc. (CTOR)|HURA (TuHURA Biosciences Inc.) - Company Aggregate Debts|Company Aggregate Debts Protara Tx|Company Aggregate Debts FATE|aadibio.com - Company Aggregate Debt|Company Debts TScan Therapeutics, Inc. TCRX|Champions Oncology Inc - Company Debts|XBiotech USA - Company Aggregate Debts|CVM - Company Aggregate Debts|OSTX: Company Aggregate Debts|RADX - Company Total Debt Obligations|Company Total Debt ARTV|VERU: Aggregate Debt Obligations|Company Debts Tempest Tx (TPST)|xiliotx.com - Company Aggregate Debt|Company Debts Renovaro RENB|Mural Oncology PLC (MURA) - Company Cumulative Debt|KAPA - Company Debts|Aggregate Debt Obligations OKUR (OnKure Therapeutics Inc)|GDTC (w2.cytomed.sg) - Company Total Debt|CRIS: Company Cumulative Indebtedness|Company Total Debt APLM|Company Cumulative Debt tharimmune.com THAR|Company Aggregate Debts ADVB|GNPX - Company Cumulative Debt|Calidi Biotherapeutics, Inc. - Company Total Debt|Aggregate Debt Obligations SBFM|XBIO - Company Debts|SLRX: Company Debts|PPBT (Purple Biotech Ltd.) - Company Total Debt|AONC: Company Cumulative Indebtedness|BGNE (BeOne Medicines) - Company Aggregate Debts|Company Aggregate Debt CKPT (Checkpoint Therapeutics Inc)|Company Total Debt ELEV (Elevation Oncology)|Company Total Debt Obligations icadmed.com|Company Aggregate Debts IKNA (Ikena Oncology)|Company Aggregate Debts Notable Labs Ltd NTBL|VIRX - Company Debts|MOR (MorphoSys Corporation) - Company Aggregate Debt|NAYA Biosciences (NAYA) - Company Debts|AAPGV (ascentage.com) - Company Debts